# Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

> **NCT01576029** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 2 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** CABAZITAXEL (XRP6258)
- **DRUG:** DOCETAXEL (XRP6976)

## Key facts

- **NCT ID:** NCT01576029
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2013-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576029, "Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01576029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*